[go: up one dir, main page]

MX2017010908A - Vacuna bivalente contra el virus de gripe porcina. - Google Patents

Vacuna bivalente contra el virus de gripe porcina.

Info

Publication number
MX2017010908A
MX2017010908A MX2017010908A MX2017010908A MX2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A
Authority
MX
Mexico
Prior art keywords
swine influenza
present
subject
bivalent
influenza virus
Prior art date
Application number
MX2017010908A
Other languages
English (en)
Inventor
Martin Vaughn Eric
Allan Eichmeyer Marc
Scott JOHNSON Wesley
L Walz Michelle
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2017010908A publication Critical patent/MX2017010908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere, entre otros, a una composición inmunogénica que comprende: a) un virus H3 vivo modificado de gripe porcina, y b) un virus H1 vivo modificado de gripe porcina. Por otra parte, la presente invención se refiere a métodos para inmunizar un sujeto que comprende la administración a tal sujeto de la composición inmunogénica de la presente invención. Más aún, la presente invención se refiere a métodos de tratamiento o prevención de los signos clínicos causados por virus de la gripe porcina en un sujeto que lo necesita, que comprende la administración al sujeto de una cantidad terapéuticamente efectiva de una composición inmunogénica de acuerdo con la presente invención.
MX2017010908A 2015-02-26 2016-02-23 Vacuna bivalente contra el virus de gripe porcina. MX2017010908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121181P 2015-02-26 2015-02-26
PCT/US2016/019037 WO2016137929A1 (en) 2015-02-26 2016-02-23 Bivalent swine influenza virus vaccine

Publications (1)

Publication Number Publication Date
MX2017010908A true MX2017010908A (es) 2017-12-07

Family

ID=55487152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010908A MX2017010908A (es) 2015-02-26 2016-02-23 Vacuna bivalente contra el virus de gripe porcina.

Country Status (13)

Country Link
US (2) US10029005B2 (es)
EP (1) EP3261664A1 (es)
JP (1) JP6722686B2 (es)
KR (1) KR20170122786A (es)
CN (1) CN107250353B (es)
AU (1) AU2016222962B2 (es)
BR (1) BR112017015789A2 (es)
CL (2) CL2017001961A1 (es)
EA (1) EA201791907A1 (es)
MX (1) MX2017010908A (es)
PH (1) PH12017501370A1 (es)
TW (1) TWI711462B (es)
WO (1) WO2016137929A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083286A2 (en) 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
EP3727444A1 (en) 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
US20210189506A1 (en) * 2017-12-20 2021-06-24 Boehringer Ingelheim Vetmedica Gmbh Detection of modified live swine influenza virus vaccines
US11464852B2 (en) * 2018-09-20 2022-10-11 Boehringer Ingelheim Vetmedica Gmbh Modified PEDV spike protein
EP4516907A3 (en) * 2018-09-21 2025-08-27 Board of Regents of the University of Nebraska Methods of making and using universal centralized influenza vaccine genes
EA202191147A1 (ru) * 2018-10-31 2021-08-23 Бёрингер Ингельхайм Ветмедика Гмбх Вакцина виб h52 с гетерологичным шиповидным белком
UA129674C2 (uk) * 2018-10-31 2025-07-02 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти вірусу інфекційного бронхіту 4/91 з гетерологічним шиповидним білком
MX2019014943A (es) * 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
CA3130781A1 (en) * 2019-02-27 2020-09-03 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses
US11541115B2 (en) * 2019-11-29 2023-01-03 Boehringer Ingelheim Vetmedica Gmbh Triple vaccine against avibacterium paragallinarum and avian encephalomyelitis virus and fowl pox virus
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230248817A1 (en) * 2020-06-19 2023-08-10 Intervet Inc. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
CN113186173B (zh) * 2021-04-15 2023-03-31 上海生物制品研究所有限责任公司 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5939831A (ja) 1982-08-27 1984-03-05 Biseibutsu Kagaku Kenkyusho:Kk 豚用インフルエンザウイルス不活化ワクチン
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
JPS60202827A (ja) 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5766601A (en) 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE69223638T2 (de) 1991-10-07 1998-05-20 Biogen, Inc., Cambridge, Mass. Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
CA2096159C (en) 1992-05-14 2004-07-20 Hermann Katinger Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DK0780475T4 (da) 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
ATE451451T1 (de) 1996-07-15 2009-12-15 Us Gov Health & Human Serv Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
AU4427897A (en) 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
EP0975809A4 (en) 1997-03-05 2002-10-30 Univ Washington EXAMINATION PROCEDURE FOR DETECTING AGENTS FOR SELECTIVE INHIBITION OF HCV REPLICATION
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
AU7797798A (en) 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
DK1012244T3 (da) 1997-07-11 2007-09-10 Univ Yale Rhabdovira med genteknologisk manipulerede kapper
CA2302867A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
CA2334850C (en) 1998-06-12 2013-11-26 Mount Sinai School Of Medicine Of The City University Of New York Novel methods and interferon deficient substrates for the propagation of viruses
CA2334857C (en) 1998-06-12 2012-03-20 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
EP1194580B2 (en) 1999-07-14 2010-08-25 Mount Sinai School of Medicine of New York University In vitro reconstitution of segmented negative-strand rna viruses
EP1259629B1 (en) 2000-03-02 2005-07-20 Polymun Scientific Immunbiologische Forschung GmbH Recombinant influenza a viruses
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
KR20030061810A (ko) 2000-09-25 2003-07-22 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 생균 백신과 제조 방법
JP2006506101A (ja) 2002-11-13 2006-02-23 ルトガーズ、ザ ステイト ユニバーシティ インフルエンザウイルス非構造タンパク質１の阻害剤を設計する方法
WO2006083286A2 (en) * 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
AT502275B8 (de) 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
AU2006320490A1 (en) 2005-12-02 2007-06-07 The Mount Sinai School Of Medicine Of New York University Chimeric viruses presenting non-native surface proteins and uses thereof
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
CN102166352B (zh) * 2011-04-13 2013-01-23 华威特（北京）生物科技有限公司 猪流感二价灭活疫苗的制备方法及其产品
US20130189303A1 (en) * 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
US9017694B2 (en) * 2011-10-07 2015-04-28 Medimmune, Llc Swine influenza hemagglutinin variants
CN103468647B (zh) * 2013-09-03 2015-04-22 华中农业大学 猪流感h1n1和h3n2亚型的二价灭活疫苗
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신

Also Published As

Publication number Publication date
EA201791907A1 (ru) 2018-02-28
KR20170122786A (ko) 2017-11-06
JP6722686B2 (ja) 2020-07-15
US20160250318A1 (en) 2016-09-01
BR112017015789A2 (pt) 2018-03-27
US10905756B2 (en) 2021-02-02
CN107250353B (zh) 2021-07-23
WO2016137929A1 (en) 2016-09-01
US20180289795A1 (en) 2018-10-11
JP2018512388A (ja) 2018-05-17
AU2016222962B2 (en) 2020-05-21
TW201701900A (zh) 2017-01-16
CL2017001961A1 (es) 2018-04-20
CL2018002692A1 (es) 2019-01-18
EP3261664A1 (en) 2018-01-03
TWI711462B (zh) 2020-12-01
US10029005B2 (en) 2018-07-24
AU2016222962A1 (en) 2017-07-13
CN107250353A (zh) 2017-10-13
PH12017501370A1 (en) 2017-12-18

Similar Documents

Publication Publication Date Title
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
PH12018500856A1 (en) Respiratory syncytial virus vaccine
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
MX2021002989A (es) Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio y reproductivo porcino y metodos de produccion de esta.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
EA201792593A1 (ru) Пестивирусные вакцины против врожденного тремора
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
EA201892003A1 (ru) Лечение атопического дерматита собак
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
MX2014001158A (es) Virus recombinantes de influenza porcina y usos del mismo.
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
EP4461365A3 (en) Respiratory syncytial virus (rsv) vaccine
IN2013MU03428A (es)
MX388528B (es) Vacuna que comprende toxoides de clostridium.